TY  - JOUR
AU  - Garcia-Carbonero, Rocio
AU  - Salazar, Ramon
AU  - Duran, Ignacio
AU  - Osman-Garcia, Ignacio
AU  - Paz-Ares, Luis
AU  - Bozada, Juan M
AU  - Boni, Valentina
AU  - Blanc, Christine
AU  - Seymour, Len
AU  - Beadle, John
AU  - Alvis, Simon
AU  - Champion, Brian
AU  - Calvo, Emiliano
AU  - Fisher, Kerry
PY  - 2017
DO  - 10.1186/s40425-017-0277-7
UR  - http://hdl.handle.net/10668/11588
T2  - Journal for immunotherapy of cancer
AB  - Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study assessed intravenous (IV) delivery of enadenotucirev in patients with resectable colorectal...
LA  - en
KW  - Adenoviruses, Human
KW  - Administration, Intravenous
KW  - CD8-Positive T-Lymphocytes
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Carcinoma, Renal Cell
KW  - Carcinoma, Transitional Cell
KW  - Colorectal Neoplasms
KW  - Combined Modality Therapy
KW  - DNA, Viral
KW  - Digestive System Surgical Procedures
KW  - Humans
KW  - Lung Neoplasms
KW  - Oncolytic Virotherapy
KW  - Oncolytic Viruses
KW  - Pulmonary Surgical Procedures
KW  - Treatment Outcome
KW  - Urologic Surgical Procedures
TI  - Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.
TY  - research article
VL  - 5
ER  -